2SPD-013 Economic impact of the use of flat dose vs personalised dose of pembrolizumab

Pires, Vitoria; Ribeiro, MJ; Gouveia, Andre G

doi:10.1136/ejhpharm-2019-eahpconf.53

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, pembrolizumab was hampered by its extremely high cost [21]. Moreover, the SD was reported to lead to unnecessary dose and economic impacts in patients who were a standard weight [22][23][24]. Goldstein et al showed that a pembrolizumab dose reduction strategy could save approximately 24.0% of the annual cost, compared with the cost of the 200 mg fixed dose [23].…”

Section: Introductionmentioning

confidence: 99%

Modified-Dose Pembrolizumab and Prognostic Outcomes among Non-Small Cell Lung Cancer Patients: A Chart Review Study

Shih

et al. 2022

IJERPH

View full text Add to dashboard Cite

The modified dose (MD) regimen of pembrolizumab (2 mg/kg or 100 mg every 3 weeks) is an alternative option to reduce the financial burden resulting from the extremely high cost of the standard dose (SD) regimen (200 mg every 3 weeks). However, the clinical effectiveness and prognostic outcomes have not been fully elucidated in real-word clinical practice. Sixty-four consecutive patients in Taiwan receiving pembrolizumab for advanced NSCLC between 2018 and 2020 were recruited in this study. Comparisons of overall survival (OS) and progression-free survival (PFS) were performed using Kaplan–Meier survival curves. Additionally, 12 predictors, including pembrolizumab regimen, dose, neutrophil-to-lymphocyte ratio (NLR), age, sex, histopathology, smoking history, ECOG PS, EGFR mutation, PD-L1 expression, distant metastases and treatment line, were analyzed in multivariable Cox models for predicting OS and PFS. The results showed that the MD group and the SD group had similar OS and PFS, especially in patients beyond first-line treatment or with a pretreatment NLR < 5. The NLR was the only independent factor associated with both OS (adjusted HR = 0.052; p = 0.010) and PFS (adjusted HR = 0.259; p = 0.021). The results of this study assure the clinical effectiveness of MD pembrolizumab and suggest that the pretreatment NLR could highlight patients who may benefit from MD pembrolizumab.

show abstract

Section: Introductionmentioning

confidence: 99%

Modified-Dose Pembrolizumab and Prognostic Outcomes among Non-Small Cell Lung Cancer Patients: A Chart Review Study

Shih

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

2SPD-013 Economic impact of the use of flat dose vs personalised dose of pembrolizumab

Abstract: ConclusionThe pharmaceutical process with the highest productivity was elaboration of cytotoxic drugs. The processing of EA vs 'off-label' in oncology means 92.4% of total management activity.

Cited by 1 publication

References 0 publications

Modified-Dose Pembrolizumab and Prognostic Outcomes among Non-Small Cell Lung Cancer Patients: A Chart Review Study

Modified-Dose Pembrolizumab and Prognostic Outcomes among Non-Small Cell Lung Cancer Patients: A Chart Review Study

Contact Info

Product

Resources

About